• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Drug-Device Combinations

Tandem Diabetes care launches Mobi pump on Android phones

March 4, 2026 By Sean Whooley

Tandem Mobi insulin pump with Android smartphone (1)

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made its Mobi automated insulin delivery system available with Android devices. San Diego-based Tandem said Mobi, the world’s smallest, durable automated insulin delivery system, can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. In November, Tandem announced that it received […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Tandem Diabetes Care

Airiver Medical wins FDA breakthrough nod for drug-coated balloon, treats first patient

March 4, 2026 By Sean Whooley

Airiver Medical Drug-Coated Balloon DCB (1) (1)

Airiver Medical announced today that it received FDA breakthrough device designation for its pulmonary drug-coated balloon (DCB). Additionally, Airiver announced the first treated patients in a clinical trial for the DCB. The Brooklyn Park, Minnesota-based company designed its DCB to treat central airway stenosis. Central airway stenosis (airway narrowing) can lead to prolonged intubation, tracheostomy, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: Airiver Medical, FDA

Modular Medical prices $12M public offering to support insulin pump

March 4, 2026 By Sean Whooley

Modular Medical Logo (1)

Modular Medical (Nasdaq:MODD) announced the pricing of a public offering worth proceeds of approximately $12 million. San Diego-based Modular Medical’s offering includes nearly 68.1 million shares of the company’s common stock and warrants to purchase up to an aggregate of 68.1 million shares. The company priced the offering at $0.1762 per share and accompanying warrant. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Technology Tagged With: modularmedical

Judge tosses class action suit accusing Abbott of sharing CGM data with Meta, Google

March 3, 2026 By Sean Whooley

Abbott FreeStyle Libre 2

An Illinois judge sided with Abbott (NYSE:ABT) in a lawsuit related to alleged data sharing with its continuous glucose monitors (CGMs). In September 2024, a lawsuit filed in the Northern District of Illinois alleged that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. The company’s FreeStyle.Abbott website […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Technology Tagged With: abbott

Kevin Sayer returns from leave of absence to chair Dexcom board

March 2, 2026 By Sean Whooley

Kevin Sayer Headshot

Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer notified the San Diego-based continuous glucose monitor (CGM) maker of his plan to return on Feb. 27, 2026. His return went into effect today, March 2, 2026, according to the filing. Upon his return, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel, Personnel Moves

Senseonics earns FDA IDE for next-gen Gemini CGM, posts Q4 revenue beat

March 2, 2026 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) posted fourth-quarter results that proved mixed compared to Wall Street forecasts alongside a major pipeline announcement. Along with its fourth-quarter results, the company shared that it secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Patient Monitoring, Regulatory/Compliance, Technology, Wall Street Beat Tagged With: Senseonics

Dexcom adds Google exec to its board

February 27, 2026 By Sean Whooley

Rick Osterloh Google Dexcom Board (1)

Dexcom (Nasdaq:DXCM) announced that it appointed Rick Osterloh to its board of directors, effective Feb. 26, 2026. Osterloh currently serves as SVP, Platforms and Devices at Google. There, he leads a unified group spanning the tech giant’s portfolio of advanced consumer technologies. San Diego-based Dexcom said in a news release that Osterloh offers significant experience […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel Moves

Medtronic launches MiniMed Go smart MDI system with Simplera sensor in Europe

February 25, 2026 By Sean Whooley

Medtronic MiniMed Go InPen Simplera CGM (1)

Medtronic (NYSE:MDT) announced today that it launched its MiniMed Go smart multiple daily injection (MDI) system with the Simplera sensor. The system represents the first and only solution that integrates data from the InPen smart insulin pen and the Simplera continuous glucose monitor (CGM) sensor into a single mobile app. Medtronic (soon to separate its Diabetes […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Medtronic, minimed

Tandem Diabetes Care prices upsized $265M offering

February 25, 2026 By Sean Whooley

Tandem Diabetes Care updated logo

Tandem Diabetes Care (Nasdaq:TNDM) today announced the pricing of a $265 million offering of convertible senior notes. San Diego-based Tandem earlier this week announced its intent to offer $200 million in notes, due 2032, in a private placement. It now says it upsized that offering by $65 million. The company also granted initial purchasers an […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Technology, Wall Street Beat Tagged With: Tandem Diabetes Care

Medtronic MiniMed Diabetes IPO could reach up to $784M

February 24, 2026 By Sean Whooley

Minimed

In an amendment to an SEC filing, Medtronic’s (NYSE:MDT) Diabetes unit, MiniMed, today shared more details on its planned initial public offering (IPO). Medtronic announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. In that announcement, the company projected the separation within the next 18 months. It […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO), Patient Monitoring, Technology, Wall Street Beat Tagged With: Medtronic, minimed

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Interim pages omitted …
  • Page 374
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS